Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Mar;58(1):34-40.
doi: 10.1111/adj.12019. Epub 2013 Jan 30.

Local drug delivery of 0.5% azithromycin in the treatment of chronic periodontitis among smokers

A R Pradeep  1 , P Bajaj, E Agarwal, N S Rao, S B Naik, N Kalra, N Priyanka
Affiliations
Free article
Randomized Controlled Trial

Local drug delivery of 0.5% azithromycin in the treatment of chronic periodontitis among smokers

A R Pradeep et al. Aust Dent J. 2013 Mar.
Free article

Erratum in

  • Aust Dent J. 2013 Jun;58(2):272. Priyanaka, N [corrected to Priyanka, N]

Abstract

Background: Along with conventional periodontal surgical therapy, local delivery of antibiotics may provide more effective treatment in smokers by targeting tissue-invasive bacteria. The aim of this randomized, placebo-controlled, double-masked clinical trial was to evaluate the adjunctive effects of subgingivally delivered 0.5% azithromycin (AZM) as an adjunct to scaling and root planing (SRP) in the treatment of chronic periodontitis in smokers.

Methods: Fifty-four patients were randomized and categorized into two treatment groups: Group 1 - 26 subjects who received (SRP) plus placebo gel and Group 2 - 28 subjects who received (SRP) plus 0.5% azithromycin. Clinical parameters were recorded at baseline, 3, 6 and 9 months. They included Plaque Index (PI), modified Sulcus Bleeding Index (mSBI), probing depth (PD) and clinical attachment level (CAL).

Results: Azithromycin resulted in significant improvements. A single application of AZM resulted in attachment gain at 9 months of 2.44 ± 0.64 mm as compared to 0.18 ± 0.68 mm for the placebo. Similarly, pocket depth and PI were significantly reduced but no change in the mSBI was noted.

Conclusions: When compared to the placebo, the adjunctive use of 0.5% AZM resulted in significant improvement in clinical outcome in the treatment of chronic periodontitis among smokers.

PubMed Disclaimer

Publication types